GA
TEVA icon

Glenhill Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Glenhill Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-88,004
Closed -$4.71M – 48
2016
Q1 		$4.71M Sell
88,004
-1,138,101
-93% -$66.8M 0.29% 33
2015
Q4 		$80.5M Buy
1,226,105
+383,672
+46% +$23.7M 5.98% 5
2015
Q3 		$47.6M Buy
+842,433
New +$54.6M 3.73% 8

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenhill Advisors's TEVA Position: Q2 2016 in Review

Glenhill Advisors sold out of Teva Pharmaceuticals (TEVA) in Q2 2016, closing a stake of 88,004 shares — an estimated $4.71M sold.

Glenhill Advisors first reported a position in TEVA in Q3 2015 and held it in 3 quarters. The position peaked at $80.5M in Q4 2015. 812 funds tracked by Wall St. Rank hold TEVA as of Q2 2016.

  • Glenhill Advisors reported no remaining Teva Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Glenhill Advisors sold 88,004 Teva Pharmaceuticals shares in Q2 2016, an estimated $4.71M.
  • Glenhill Advisors first reported a position in Teva Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Glenhill Advisors's Teva Pharmaceuticals position peaked at $80.5M in Q4 2015.
  • 812 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2016.

Based on Glenhill Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.